Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0035 for Corneal Epithelial Wound Healing
NCT02929823Phase 2Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fonadelpar in corneal epithelial disorders (3 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5. Started Sep 2016; status: completed.
02
Drugs
fonadelpar
03
Conditions
corneal epithelial disorders
Beyond the preview
Go deeper on NCT02929823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929823.